GLP-1s Reduce Inflammation Traditional cardiology frames heart disease as a plumbing problem arteries slowly clog until fully blocked which is why a standard lipid panel focuses almost entirely on cholesterol
Sermorelin is used in GH/IGF-1 axis research, pituitary somatotroph function models, and preclinical studies of GHRH-receptor pharmacology
Kaber G, Kratochvil MJ, Burgener EB, Peltan EL, Barlow G, Yang S, et al
Cell Death Dis 16(1):259 Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at 61st EASD Annual Meeting 2025, Wien [press release] Dalton JT, Barnette KG, Bohl CE, Hancock ML, Rodriguez D, Dodson ST et al (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial
Tirzepatide is a dual-action agonist as it enhances both GLP-1 and another hormone known as glucose-dependent insulinotropic polypeptide (GIP) to improve blood sugar control as well as reduce appetite and food intake
When a promising medication like semaglutide enters the picture, the question is not should we use this instead of therapy? The real question is: How do we integrate this into an evidence-based treatment plan that addresses the whole person? That is where psychiatry services become essential